Research Partners & Collaborators
At Abeona, collaboration fuels innovation. Our clinical progress is made possible through strategic partnerships with leading research institutions, advocacy organizations and healthcare providers who share our commitment to transform care for patients with serious diseases.
Our FDA-approved treatment, ZEVASKYN®, as well as our lead pipeline asset ABO-701, demonstrate how Abeona is validating scientific discovery and setting the stage for future breakthroughs. Innovations like the Synthetic Immune Receptor (SIR) technology, that was purposefully designed to overcome the fundamental limitations of Chimeric Antigen Receptors (CARs), are emblematic of the breakthrough potential that collaborations can enable. Our partnerships not only accelerate development but also expand access, deepen impact and help open doors to new possibilities in cell and gene therapies.
Partnered Programs
Ultragenyx
UX111 AAV gene therapy for Sanfilippo syndrome type A (MPS IIIA)
Taysha Gene Therapies
TSHA-102 for Rett syndrome
